facebook pixel

NOW AVAILABLE IN THE US

Firdapse (amifampridine) Tablets 10mg

Now there’s an FDA-approved, first-line treatment for adults with LEMS.1,2

INDICATIONS AND USAGE: FIRDAPSE® is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS FIRDAPSE® is contraindicated in patients with:

  • A history of seizures
  • Hypersensitivity to amifampridine phosphate or another aminopyridine

WARNINGS AND PRECAUTIONS Seizures: FIRDAPSE® can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE® in patients who have a seizure while on treatment. FIRDAPSE® is contraindicated in patients with a history of seizures. Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE® should be discontinued and appropriate therapy initiated. ADVERSE REACTIONS The most common adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1844-FIRDAPSE) or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.

It's All About The Company You Keep

Catalyst Pharmaceuticals is committed to improving the lives of people with rare diseases

NOW FDA APPROVED

It's All About The Company You Keep

Catalyst Pharmaceuticals is committed to improving the lives of people with rare diseases

Firdapse (amifampridine) Tablets 10mg

Now there’s an FDA-approved, first-line treatment for adults with LEMS.1,2

INDICATIONS AND USAGE: FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
FIRDAPSE is contraindicated in patients with:

  • A history of seizures
  • Hypersensitivity to amifampridine phosphate or another aminopyridine

WARNINGS AND PRECAUTIONS
Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures.
Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.
ADVERSE REACTIONS
The most common adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.
To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1844-FIRDAPSE) or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.

At Catalyst Pharmaceuticals, we understand that receiving a rare disease diagnosis can be extremely difficult. Often patients feel isolated and hopeless. That’s why we believe that, when you’re battling a rare disease—it’s all about the company you keep.

Our company is committed to developing novel, safe, and efficacious therapies that will improve the lives of people with rare and ultra-rare diseases.